Figure 6.

MEK1/2 inhibitor treatment differentially modulates malaria-induced pro- and anti-inflammatory responses by DCs in vivo. A–D, PbA-infected mice were treated i.p. with 3 mg of PD/kg body weight or vehicle daily starting at 6 h pi. A, serum cytokine levels at 4 and 6 days pi in PbA-infected mice assessed by ELISA. B–D, spleen cells from the infected mice were analyzed by flow cytometry for cytokine production by DCs at 3 and 5 days pi (C) and costimulatory molecule expression (D) by DCs at 4 days pi. The gating strategy for the CD11c^hiMHCII^hiCD8α⁺ and CD11c^hiMHCII^hiCD8α⁻ DC subsets is shown in B. The gating strategy for cytokine⁺ spleen DCs is shown in supplemental Fig. S3. Isotype-specific antibodies were used as control. A–D, the results are a representative of four independent experiments; n = 3 mice/group in each experiment. Statistical analysis was by one-way ANOVA with Newman–Keuls correction for multiple comparisons. Error bars, S.D. *, p < 0.05; **, p < 0.01; ***, p < 0.001.